265 related articles for article (PubMed ID: 34145035)
41. Emerging roles of the CIP2A-TopBP1 complex in genome integrity.
Ummethum H; Li J; Lisby M; Oestergaard VH
NAR Cancer; 2023 Dec; 5(4):zcad052. PubMed ID: 37829116
[TBL] [Abstract][Full Text] [Related]
42. CIP2A is associated with human breast cancer aggressivity.
Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
[TBL] [Abstract][Full Text] [Related]
43. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
44. Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the Discovery of drug candidates against triple negative breast cancer (TNBC).
Ibitoye O; Ibrahim MAA; Soliman MES
J Recept Signal Transduct Res; 2023 Dec; 43(6):133-143. PubMed ID: 38166612
[TBL] [Abstract][Full Text] [Related]
45. Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer.
Liu K; Bellam N; Lin HY; Wang B; Stockard CR; Grizzle WE; Lin WC
Mol Cell Biol; 2009 May; 29(10):2673-93. PubMed ID: 19289498
[TBL] [Abstract][Full Text] [Related]
46. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer.
Ma L; Wen ZS; Liu Z; Hu Z; Ma J; Chen XQ; Liu YQ; Pu JX; Xiao WL; Sun HD; Zhou GB
PLoS One; 2011; 6(5):e20159. PubMed ID: 21655278
[TBL] [Abstract][Full Text] [Related]
47. The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation.
Kim SH; Lee WH; Seong D; An JH; Je HU; Nam HY; Kim SY; Kim SW; Han MW
Head Neck; 2019 Sep; 41(9):3362-3371. PubMed ID: 31268585
[TBL] [Abstract][Full Text] [Related]
48. TopBP1 is required at mitosis to reduce transmission of DNA damage to G1 daughter cells.
Pedersen RT; Kruse T; Nilsson J; Oestergaard VH; Lisby M
J Cell Biol; 2015 Aug; 210(4):565-82. PubMed ID: 26283799
[TBL] [Abstract][Full Text] [Related]
49. Depletion of CIP2A inhibits the proliferation, migration, invasion and epithelial-mesenchymal transition of glioma cells.
Xu Z; Chen X; Hegazy AM; Zhang S; Liu X; Tian J; Wu J; Shi F; Li L; Niu X; Pu J
Brain Res Bull; 2021 Aug; 173():14-21. PubMed ID: 33892085
[TBL] [Abstract][Full Text] [Related]
50. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
[TBL] [Abstract][Full Text] [Related]
51. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
52. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
Wang J; Okkeri J; Pavic K; Wang Z; Kauko O; Halonen T; Sarek G; Ojala PM; Rao Z; Xu W; Westermarck J
EMBO Rep; 2017 Mar; 18(3):437-450. PubMed ID: 28174209
[TBL] [Abstract][Full Text] [Related]
53. CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
Wu Y; Gu TT; Zheng PS
Cancer Lett; 2015 Jan; 356(2 Pt B):646-55. PubMed ID: 25458953
[TBL] [Abstract][Full Text] [Related]
54. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
Moudry P; Watanabe K; Wolanin KM; Bartkova J; Wassing IE; Watanabe S; Strauss R; Troelsgaard Pedersen R; Oestergaard VH; Lisby M; Andújar-Sánchez M; Maya-Mendoza A; Esashi F; Lukas J; Bartek J
J Cell Biol; 2016 Feb; 212(3):281-8. PubMed ID: 26811421
[TBL] [Abstract][Full Text] [Related]
55. CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin.
Gao F; Xu T; Wang X; Zhong S; Chen S; Zhang M; Zhang X; Shen Y; Wang X; Xu C; Shen Z
J Exp Clin Cancer Res; 2017 May; 36(1):70. PubMed ID: 28521777
[TBL] [Abstract][Full Text] [Related]
56. Phosphorylation of the BRCA1 C terminus (BRCT) repeat inhibitor of hTERT (BRIT1) protein coordinates TopBP1 protein recruitment and amplifies ataxia telangiectasia-mutated and Rad3-related (ATR) Signaling.
Zhang B; Wang E; Dai H; Shen J; Hsieh HJ; Lu X; Peng G
J Biol Chem; 2014 Dec; 289(49):34284-95. PubMed ID: 25301947
[TBL] [Abstract][Full Text] [Related]
57. Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A.
Fujiki H; Sueoka E; Watanabe T; Komori A; Suganuma M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9425-9433. PubMed ID: 37097392
[TBL] [Abstract][Full Text] [Related]
58. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
59. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
60. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
